GlassScriptPhysician profile
Mildred Olivier
NPI 1063508190
$56,075.55
in general payments reported to CMS, 2019-2025
20 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $11K · 2021: $6,702 · 2022: $4,373 · 2023: $4,742 · 2024: $3,320 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,788 · Food and Beverage: $2,800 · Honoraria: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,787.50 |
| Food and Beverage | $2,800.15 |
| Honoraria | $2,363.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $28,680.96 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $8,080.55 | 2019-2020 | |
| Horizon Therapeutics Plc | $4,406.37 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $4,053.00 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $3,213.68 | 2020-2021 | |
| Abbvie INC. | $2,815.91 | 2022-2025 | |
| Amgen INC. | $2,173.56 | 2024 | Tepezza |
| Alcon Vision LLC | $629.11 | 2019-2025 | Rocklatan, Hydrus Microstent, Centurion |
| Sun Pharmaceutical Industries INC. | $400.75 | 2021-2024 | |
| Thea Pharma INC. | $268.00 | 2023 | |
| New World Medical,INC. | $248.36 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $243.02 | 2019-2024 | Tecnis Simplicity, Veritas Vision System |
| Sight Sciences, INC. | $166.90 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Carl Zeiss Meditec USA, INC. | $134.75 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $134.35 | 2024-2025 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $133.48 | 2020 | |
| Oyster Point Pharma, INC. | $108.16 | 2024 | Ryzumvi, Tyrvaya |
| Glaukos Corporation | $102.18 | 2021-2024 | Radius |
| Carl Zeiss Meditec Ag | $58.20 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mildred Olivier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.